IL2 and neoplasm: To deliver functionally active cytokines, that are found to be critical for establishing and maintaining the immune response to tumors, preferentially at the tumor site, the Frelinger group developed an activatable IL-2 fusion protein consisting of IL-2 joined to a specific IL-2 binder that blocks its function connected by a KLK3 cleavage sequence (161).